{"filings":[{"id":2088238,"accession_number":"0001819790-26-000063","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2026-08-06T11:23:01+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q2 XDEMVY sales $173.9M (+69% YoY); raises FY guidance to $685-705M; acquires Alkeus","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["XDEMVY net product sales $173.9M in Q2 2026, up >69% YoY; full-year guidance raised to $685-705M.","Net loss narrowed to $18.6M ($0.43 loss per share) from $20.3M ($0.48) in Q2 2025.","Cash, cash equivalents and marketable securities $449.7M as of June 30, 2026.","Announced agreement to acquire Alkeus Pharmaceuticals (Phase 3 Stargardt disease therapy) and $125M private placement.","Appointed Neera Clase as Interim Chief Commercial Officer; pipeline milestones on track."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2088160,"accession_number":"0001819790-26-000062","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2026-08-06T11:11:10+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Tarsus Pharmaceuticals raises $125M in oversubscribed PIPE financing at $56/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$125M from sale of 2,098,519 shares at $56.00 and pre-funded warrants for 133,625 shares at $55.9999.","PIPE includes participation from Alkeus investors (TCGX, Bain Capital, Wellington) and new investors (ADAR1, Sirenia, RTW, Vestal Point).","Proceeds to fund clinical development, commercial activities, and general corporate purposes; closing expected Aug 7, 2026.","PIPE is in connection with pending acquisition of Alkeus Pharmaceuticals (announced separately).","Barclays lead placement agent; BofA Securities and William Blair co-placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2088116,"accession_number":"0001819790-26-000060","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2026-08-06T11:08:34+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Tarsus to acquire Alkeus for $450M upfront; adds Phase 3 Stargardt drug gildeuretinol","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront consideration: $270M cash + $180M in Tarsus stock ($61.38/share); total ~$450M.","Milestones up to $350M (regulatory approval + first commercial sale) plus low-single-digit royalties.","Gildeuretinol (ALK-001) is a once-daily oral for Stargardt disease; no FDA-approved therapy exists.","Phase 3 NORTHSTAR trial enrolling ~230 patients; topline data expected H2 2029.","Deal approved by both boards; expected to close in 2026, subject to HSR clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1610036,"accession_number":"0001819790-26-000048","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2026-07-13T20:11:59+00:00","items":["5.02"],"status":"ready","headline":"Tarsus CCO Aziz Mottiwala departing July 15 to become CEO of another public med device company","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Aziz Mottiwala to leave role as Chief Commercial Officer and employment on July 15, 2026.","Mottiwala is departing to become CEO of a public medical device company.","No successor or interim CCO has been announced by Tarsus Pharmaceuticals.","Announcement made on July 13, 2026; departure is voluntary for an external CEO opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1526316,"accession_number":"0001819790-26-000046","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2026-07-08T20:13:40+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Tarsus acquires iRenix Medical for ~$75M upfront; adds late-stage ocular antiseptic IRX-101","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront consideration of $75M: $37.5M cash + $37.5M in Tarsus common stock (607,093 shares).","Potential approval/commercial milestones up to $490M plus low-to-mid single-digit revenue sharing.","IRX-101 Phase 2b/3 RELIEF trial: ~50% relative reduction in post-procedural pain (p=0.0003) vs povidone-iodine.","Phase 3 study expected to start H1 2027 with results in 2028; FDA-aligned program.","Over 11M intravitreal injections performed annually in US; no new FDA-approved ocular antiseptic in >40 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1333676,"accession_number":"0001819790-26-000043","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2026-06-29T20:19:53+00:00","items":["5.07"],"status":"ready","headline":"Tarsus shareholders elect four Class III directors, approve exec comp, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Wendy Yarno, Andrew Goldberg, Scott Morrison, David Pyott elected as Class III directors.","Advisory vote on named executive officer compensation approved with 34.5M for, 0.24M against.","Ratification of Ernst & Young as independent auditor for FY2026 approved with 38.2M for.","Meeting held June 25, 2026; 38.2M shares voted out of 43.0M outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95780,"accession_number":"0001819790-26-000037","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q1 XDEMVY sales $145.4M (+85% YoY); net loss narrows to $7.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["XDEMVY net product sales $145.4M vs $78.3M YoY; gross margin 94%.","Reaffirmed FY2026 XDEMVY guidance $670-700M; peak sales potential >$2B.","Net loss $7.0M ($0.16 loss per share) vs $25.1M loss ($0.64) YoY.","License fees $16.7M from $15M China regulatory milestone; cash $388.7M.","Phase 2 Calliope trial started for TP-05 Lyme disease prophylaxis; topline H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":162054000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109084,"accession_number":"0001819790-26-000017","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus reports FY2025 XDEMVY sales of $451.4M (+150% YoY); net loss narrows to $66.4M; guides peak >$2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net product sales $151.7M (Q4 2024: $66.4M); full-year $451.4M; ~400,000 bottles delivered in 2025.","Full-year net loss $66.4M ($1.59 loss per share) vs $115.6M ($3.07) in 2024; Q4 net loss $8.4M ($0.20) vs $23.1M ($0.60).","Management guided XDEMVY peak sales potential >$2B; gross margin held at 93%; cash $417.3M at year-end.","Initiated Phase 2 trial of TP-04 for ocular rosacea (topline 1H 2027); TP-05 Phase 2 for Lyme prevention expected Q2 2026.","David E.I. Pyott (former Allergan CEO) appointed to board; DTC campaign boosted patient awareness of Demodex blepharitis to ~25%."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":451360000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109083,"accession_number":"0001819790-26-000005","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tarsus appoints former Allergan CEO David Pyott to Board of Directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pyott appointed as Class III director effective Feb 18, 2026; term expires at 2026 annual meeting.","He chairs Commercial Committee and serves on Nominating and Compensation Committees; deemed independent.","Initial equity grant target $540,000 (50% options, 50% RSUs) under non-employee director policy.","Pyott served as Allergan CEO for 17 years, grew revenue from ~$1B to >$7B; also on Alnylam and Pliant boards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109082,"accession_number":"0001819790-26-000002","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tarsus Pharmaceuticals furnishes corporate presentation; no material updates identified","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation published January 12, 2026, on company website.","Presentation highlights XDEMVY eye care product; no new financial or clinical data provided.","Routine Regulation FD disclosure; no guidance changes or strategic announcements.","Furnished excerpt does not contain specific numbers or events beyond product branding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125551,"accession_number":"0001819790-25-000120","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q3 2025: XDEMVY sales $118.7M, +147% YoY; net loss narrows to $0.30/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["XDEMVY net sales of $118.7M (Q3 2024: $48.1M); >103,000 bottles delivered to patients.","Net loss of $12.6M vs $23.4M; diluted EPS $(0.30) vs $(0.61) in prior-year quarter.","Cash, equivalents & marketable securities of $401.8M as of Sept 30, 2025.","Phase 2 trial of TP-04 for ocular rosacea starting Dec 2025; Phase 2 of TP-05 for Lyme disease in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":299692000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142290,"accession_number":"0001819790-25-000107","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q2 net product sales $102.7M, up 152% YoY; net loss narrows to $20.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 net product sales $102.7M (+152% YoY); 91,000 bottles distributed.","Net loss $20.3M ($0.48 loss per share) vs $33.3M ($0.88) in Q2 2024.","Gross-to-net discount ~45%; DTC campaign drove 400% web engagement and 30% more prescribers.","Cash $381.1M; pipeline: Phase 2 TP-04 (ocular rosacea) H2 2025, TP-05 (Lyme) in 2026.","Global expansion: Japan regulatory meetings H2 2025; EU approval expected 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":180995000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160308,"accession_number":"0001819790-25-000100","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tarsus annual meeting: directors elected, say-on-pay approved, Ernst & Young ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected Bobak Azamian, M.D., Ph.D. (20.8M for) and Katherine Goodrich, M.D. (26.8M for) as Class II directors.","Non-binding advisory vote approved named executive officer compensation: 27.1M for, 416,845 against, 16,635 abstain.","Stockholders selected an every-1-year frequency for future say-on-pay votes (26.9M votes for 1 year).","Ratification of Ernst & Young LLP as independent auditor for FY2025 approved: 34.7M for, 125,755 against, 7,803 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160307,"accession_number":"0001819790-25-000077","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q1 2025: XDEMVY sales $78.3M, up 217% YoY; net loss narrows to $25.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales of XDEMVY $78.3M, up 217% vs Q1 2024 and 18% vs Q4 2024; ~72,000 bottles dispensed.","Net loss of $25.1M ($0.64 diluted loss per share), improved from $35.7M loss ($1.01 per share) in Q1 2024.","Cash, cash equivalents and marketable securities $407.9M as of March 31, 2025, bolstered by $134.8M equity offering.","SG&A expenses $85.0M, up from $51.6M, driven by DTC advertising and commercial expansion.","On track to initiate Phase 2 trial of TP-04 for Ocular Rosacea in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":78335000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178597,"accession_number":"0001819790-25-000035","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tarsus closes public offering of 3.23M shares; net proceeds $134.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters exercised full over-allotment; total shares sold: 3,230,336 (incl. 421,348 additional shares).","Shares sold to underwriters at $41.83 each; public offering price $44.50.","Net proceeds of ~$134.8M after underwriting discounts and estimated offering expenses.","Offering closed on March 14, 2025; use of proceeds not specified but typical for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178596,"accession_number":"0001193125-25-053978","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Tarsus prices upsized $125M public offering of 2.8M shares at $44.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 2,808,988 shares at public price $44.50; net proceeds ~$117.1M.","Upsized from originally proposed $100M; underwriters have 30-day option for additional 421,348 shares.","Closing expected March 14, 2025; Goldman Sachs, BofA, Barclays, Oppenheimer lead.","Offering made under effective shelf registration; use of proceeds not specified in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178595,"accession_number":"0001819790-25-000007","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q4 XDEMVY sales $66.4M; full-year $180.1M; net loss narrows to $0.60/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net product sales $66.4M (vs $13.1M YoY); full-year $180.1M (vs $14.7M), with 163,000 bottles dispensed in 2024.","Net loss $23.1M ($0.60/share) in Q4 vs $41.9M ($1.31) in Q4 2023; full-year loss $115.6M ($3.07) vs $135.9M ($4.62).","Cash and marketable securities $291.4M as of Dec 31, 2024; gross-to-net discount ~45% on XDEMVY.","Pipeline: TP-04 for ocular rosacea on track to start Phase 2 in H2 2025; TP-05 for Lyme disease Phase 2 study planned.","Appointed Dr. Elizabeth Yeu as CMO and Dr. Katherine Goodrich to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":182953000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178594,"accession_number":"0001819790-25-000003","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tarsus board member Rosemary Crane resigns, becomes consultant; committee changes","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rosemary Crane resigned from Board and committees effective Jan 17, 2025; not due to any disagreement.","Crane entered a 6-month consulting agreement with Tarsus, continuing to vest in equity awards.","Wendy Yarno appointed Chairperson of Commercial Committee; steps off Audit Committee effective Jan 17.","Andrew Goldberg, M.D. appointed to Audit Committee effective Jan 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178593,"accession_number":"0001193125-25-005030","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tarsus Pharmaceuticals posts corporate presentation on investor website","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Published January 13, 2025, on the Investor & News section of Tarsus website.","Presentation titled 'The Future of Eye Care Begins Here' filed as Exhibit 99.1.","No specific financial guidance, product updates, or material events disclosed.","Tarsus (NASDAQ: TARS) is focused on eye care, with XDEMVY as a key product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195262,"accession_number":"0001819790-24-000138","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Tarsus Pharmaceuticals signs 10-year lease for new HQ in Irvine, CA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for 59,626 sq. ft. at 17700 Laguna Canyon Road, Irvine, CA; term 120 months.","Initial monthly base rent $211,672.30, with ~3% annual increases; 5-month rent abatement (~$656,756).","Construction allowance up to ~$6 million; security deposit via $2.56M letter of credit.","Lease commences ~11 months after signing or upon start of business activities at Premises."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195261,"accession_number":"0001819790-24-000127","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q3 2024: XDEMVY sales $48.1M, net loss narrows to $23.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales of $48.1M in Q3 2024, up from $1.7M in Q3 2023; over 41,400 bottles delivered.","Net loss of $23.4M ($0.61 per share) compared to $39.1M ($1.28 per share) in Q3 2023.","Secured the two remaining large Medicare contracts; coverage now extends to >80% of covered lives.","Appointed Elizabeth Yeu, M.D. as Chief Medical Officer and Katherine Goodrich, M.D. to board.","Cash and marketable securities of $317.0M as of September 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":116545000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195260,"accession_number":"0001819790-24-000119","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tarsus appoints Elizabeth Yeu as CMO; she resigns from board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Yeu appointed Chief Medical Officer effective Nov 4, 2024; resigned from Board same date.","Annual base salary of $480,000, $25,000 signing bonus, and 45% annual incentive bonus.","Granted 27,278 RSUs vesting 25% annually over four years, and option for 41,074 shares.","Severance includes 12 months salary and benefits; accelerated vesting on change in control.","Dr. Yeu previously served as board member since Dec 2021 and consulting Chief Medical Advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211517,"accession_number":"0001819790-24-000109","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q2 2024: XDEMVY net sales $40.8M (65% QoQ), net loss $33.3M, gross-to-net improves to 44%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["XDEMVY net product sales $40.8M in Q2, up 65% over Q1; year-to-date $65.5M.","Gross-to-net discount improved to 44% from 55% in Q1; steady state expected low 40% in 2025.","More than 37,000 bottles delivered to patients in Q2; ~11,000 ECPs have started patients launch-to-date.","Net loss $33.3M (($0.88) per share) vs $31.4M in Q2 2023; SG&A $58.8M vs $20.3M due to launch costs.","Cash $323.6M including ~$39.6M from new credit facility draw; sales force expansion to ~50 additional reps by end of Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":68427000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230194,"accession_number":"0001819790-24-000087","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tarsus Pharma annual meeting elects two Class I directors, ratifies Ernst & Young auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bhaskar Chaudhuri (21.8M for, 2.9M withheld) and William Link (20.8M for, 3.9M withheld) elected as Class I directors.","Ratification of Ernst & Young as auditor for FY2024: 31.9M for, 24.9K against, 57.3K abstain.","Total shares voted: 31,978,938 out of 37,776,665 outstanding, quorum achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230193,"accession_number":"0001819790-24-000062","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q1 2024: XDEMVY sales $24.7M (+89% QoQ), net loss $35.7M, cash $298.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net product sales of XDEMVY $24.7M, up 89% from Q4 2023; ~26,000 bottles delivered (65% increase).","Net loss of $35.7M ($1.01 loss per share) vs $23.4M loss in Q1 2023.","SG&A expenses surged to $51.6M from $15.1M due to commercial launch costs.","Cash and marketable securities $298.5M as of Mar 31; secured $200M credit facility in Apr 2024 (drew $75M).","Secured commercial payer contracts covering ~18M lives on preferred status; broad coverage expected by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":27614000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230192,"accession_number":"0001819790-24-000050","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Tarsus secures $200M non-dilutive credit facility from Pharmakon; draws $75M initially","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $75M drawn April 19, 2024; used to repay Hercules Capital/SVB debt and for corporate purposes.","Additional $125M available in three tranches ($25M, $50M, $50M) through Dec 2025, subject to revenue milestones.","Interest at SOFR + 6.75% (3.75% floor); five-year interest-only, matures April 19, 2029.","No warrants or financial covenants; loan secured by substantially all assets.","Net proceeds ~$40M after repayment and fees; total committed capital from Pharmakon $200M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248622,"accession_number":"0001819790-24-000024","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tarsus Pharmaceuticals completes public offering, raising net proceeds of $107.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 3,281,250 shares and pre-funded warrants for 312,500 shares at $32.00 public price.","Underwriters exercised option in full to purchase additional 468,750 shares.","Net proceeds after discounts and expenses were approximately $107.8 million.","Offering closed March 5, 2024; led by Goldman Sachs, BofA Securities, Guggenheim Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248621,"accession_number":"0001193125-24-056209","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Tarsus prices $100M public offering of common stock and pre-funded warrants at $32/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering consists of 2,812,500 shares common stock at $32.00/share and pre-funded warrants for 312,500 shares at $31.9999 each.","Underwriters granted 30-day option to purchase up to 468,750 additional shares at $32.00 less discounts.","Gross proceeds ~$100M; net proceeds expected ~$93.7M after discounts and expenses.","Offering expected to close March 5, 2024, subject to customary conditions.","Goldman Sachs, BofA, Guggenheim, and Oppenheimer are joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248620,"accession_number":"0001819790-24-000015","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q4 XDEMVY sales $13.1M; positive Phase 2a rosacea data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["XDEMVY net product sales $13.1M in Q4, $14.7M total since late-August launch; >17,400 bottles dispensed.","Positive Phase 2a Galatea trial for TP-04 in papulopustular rosacea: statistically significant improvements in lesions and IGA score vs vehicle at Week 12.","Q4 net loss $41.9M ($1.31 EPS); full-year net loss $135.9M ($4.62 EPS).","Cash, equivalents and marketable securities $227.4M as of Dec 31, 2023.","~6,000 ECPs have started patients on XDEMVY; >50% prescribed to multiple patients as of Feb 23."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":17447000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248619,"accession_number":"0001819790-24-000006","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-01-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tarsus CMO Jose Trevejo departs; clinical dev reorganizes under COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Trevejo steps down as CMO effective Jan 18, 2024; employment ends Feb 17, 2024.","Clinical development and medical affairs reorganized under COO Dr. Sesha Neervannan.","Transition approved Jan 11, 2024; company expresses gratitude for Dr. Trevejo's service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248618,"accession_number":"0001819790-24-000004","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tarsus publishes corporate presentation; no specific financial details available","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Tarsus published a corporate presentation on its website on January 8, 2024.","Presentation includes a patient case for XDEMVY (Sulma).","No financial results or guidance disclosed in the available excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266118,"accession_number":"0001819790-23-000088","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tarsus announces positive topline Phase 2a results for TP-03 in MGD with Demodex mites","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Ersa trial evaluated TP-03 (lotilaner ophthalmic solution, 0.25%) BID or TID for 12 weeks.","Trial enrolled Meibomian Gland Disease patients with Demodex mites.","Company states positive topline results; detailed data presented in corporate deck.","No specific efficacy or safety numbers disclosed in the 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266117,"accession_number":"0001819790-23-000081","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus reports Q3 net loss $39.1M; XDEMVY launch yields $1.7M in 5 weeks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales of XDEMVY were $1.7M with ~1,700 bottles dispensed in first 5 weeks post-launch.","Net loss of $39.1M ($1.28 per share) vs. $22.5M loss ($0.84) in Q3 2022; SG&A rose to $30.3M on launch costs.","Gross-to-net discount on XDEMVY was 73%, better than anticipated; cash, equivalents and marketable securities $246.9M.","Received $99.4M net proceeds from August 2023 public equity offering; balance sheet strengthened.","XDEMVY added to AAO Preferred Practice Pattern guidelines as first FDA-approved therapy for Demodex blepharitis."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":4371000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283357,"accession_number":"0001819790-23-000070","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus posts Q2 net loss $31.4M, gets FDA nod for XDEMVY, raises $100M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $31.4M in Q2 2023 vs $5.7M loss in Q2 2022; no license revenue ($15.3M in prior year).","Cash and marketable securities $178.2M at June 30, 2023; gross proceeds of $100M from August 2023 equity offering.","FDA approved XDEMVY (lotilaner ophthalmic solution) 0.25% for Demodex blepharitis on July 24, 2023; launch expected end of August 2023.","Completed enrollment of Galatea Phase 2a trial evaluating TP-04 for Rosacea; topline data expected in 1H 2024.","Recruited 85-person sales force targeting ~15K optometrists/ophthalmologists; deployed by end of August."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":2500000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283356,"accession_number":"0001193125-23-201717","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Tarsus prices $100M public offering of 5.71M shares at $17.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net proceeds expected to be ~$93.6M after underwriting discounts and offering expenses.","Underwriters granted 30-day option to purchase up to an additional 857,142 shares.","Joint book-running managers: Goldman Sachs, BofA Securities, Guggenheim Securities, Oppenheimer.","Offering expected to close on August 4, 2023, subject to customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283355,"accession_number":"0001193125-23-199180","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tarsus Pharmaceuticals launches proposed underwritten public offering of common stock","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company commenced proposed underwritten public offering of common stock under existing shelf registration.","Terminated unused ATM prospectus; no shares were ever sold under that program.","Sales Agreement with Jefferies LLC remains in effect, pending new prospectus.","No details on size, pricing, or timing of the offering were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283354,"accession_number":"0001193125-23-192827","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"FDA approves Tarsus' XDEMVY (lotilaner) 0.25% for Demodex blepharitis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved XDEMVY (lotilaner ophthalmic solution) 0.25% for treatment of Demodex blepharitis.","Approval announced July 25, 2023 via press release and investor webcast.","Corporate presentation and webcast replay posted on Tarsus' investor website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302800,"accession_number":"0001819790-23-000064","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tarsus shareholders elect three Class III directors, ratify E&Y as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Andrew Goldberg, Scott Morrison, Wendy Yarno elected to board until 2026 annual meeting.","Director election votes: Goldberg 16.18M for, Morrison 14.67M, Yarno 16.56M; each had 4.98M broker non-votes.","Ratification of Ernst & Young as independent auditor for FY 2023 passed with 22.17M for, 7,065 against.","Annual meeting held June 22, 2023; 22.18M of 26.80M shares represented a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302799,"accession_number":"0001819790-23-000034","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tarsus hosts investor webcast on TP-03 commercialization strategy; no new material financial data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company hosted Virtual Investor Webcast on June 15, 2023, with corporate presentation on TP-03 for Demodex blepharitis.","Presentation posted to investor section of website; no specific financial results or guidance provided.","No material changes to business or financial condition disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302798,"accession_number":"0001819790-23-000028","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q1 net loss $23.4M; cash $201.2M; TP-03 PDUFA Aug 25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.4M vs $20.2M in Q1 2022; revenue $2.5M from LianBio partnership.","Cash and marketable securities $201.2M as of March 31, 2023.","TP-03 (Demodex blepharitis) PDUFA date August 25, 2023; 93% of eye doctors would prescribe if approved.","Phase 2a trials ongoing for TP-04 (rosacea), TP-05 (Lyme prevention), and TP-03 (MGD).","Appointed Jeff Farrow as CFO and Chief Strategy Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":2500000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302797,"accession_number":"0001193125-23-112926","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2023-04-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tarsus Pharma appoints Jeff Farrow as CFO and Chief Strategy Officer; Leo Greenstein departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leo Greenstein left as CFO effective April 24, 2023; employment continues through June 15, 2023.","Jeff Farrow appointed CFO and Chief Strategy Officer effective April 24, 2023; previously CFO at Global Blood Therapeutics, ZS Pharma, and Hyperion Therapeutics.","Farrow receives $500,000 base salary, $100,000 signing bonus (paid in two tranches), and 40% annual bonus target.","Equity awards: RSUs and options each with $1.5M target value; RSUs vest 25% annually over 4 years starting June 15, 2024.","Severance: 9 months base salary (non-CIC) or 12 months base plus accelerated vesting and prorated bonus (CIC)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322427,"accession_number":"0001819790-23-000004","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus reports FY2022 net loss of $62.1M; PDUFA for TP-03 on Aug 25, 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year net loss $62.1M vs $13.8M in 2021; revenue from TP-03 out-license was $25.8M.","Cash, cash equivalents and marketable securities $217.0M; runway into at least 2H 2026.","TP-03 NDA accepted; PDUFA target action date August 25, 2023 for Demodex blepharitis.","Completed enrollment of Ersa Phase 2a (MGD); topline data expected H2 2023.","Initiated Galatea Phase 2a trial of TP-04 for rosacea; Phase 1 safety supported progression."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322426,"accession_number":"0001193125-23-002528","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Tarsus extends $25M second tranche draw to March 2024, reduces interest rate on credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second tranche of $25M under loan agreement: draw period extended to March 15, 2024; minimum $5M drawn by March 15, 2023 and another $5M by Sept 15, 2023.","Third tranche of $35M available upon FDA approval of TP-03 for Demodex blepharitis; must be drawn by March 15, 2024.","First tranche balance of $20M expired undrawn on December 15, 2022.","Interest rate reduced to prime plus 4.45% (cap 11.45%) or floor 8.45%; no lender fees incurred.","Regulatory milestone for second tranche draw already achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340472,"accession_number":"0001819790-22-000045","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tarsus Pharma board chair Ackermann resigns; CEO Azamian succeeds; Yarno named lead independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Ackermann resigned as Chairperson and Board member effective Dec 2, 2022; no disagreement with company.","Ackermann entered a 12-month consulting agreement, receiving 5,000 RSUs vesting in one year and continued equity vesting.","CEO Bobak Azamian appointed Board Chairperson effective Dec 2; will not receive additional compensation.","Wendy Yarno appointed Lead Independent Director effective Dec 2; granted 5,000 RSUs vesting in one year and $75,000 annual cash retainer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340471,"accession_number":"0001819790-22-000039","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q3 net loss $22.5M; NDA accepted for TP-03 with PDUFA Aug 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.5M in Q3 2022 vs $15.7M in Q3 2021; R&D expense $10.9M, G&A $12.0M.","Cash and marketable securities $226.6M at Sep 30, 2022; runway into at least 2026.","FDA accepted TP-03 NDA for Demodex blepharitis; PDUFA target action date Aug 25, 2023.","Board changes: Scott Morrison appointed Audit Chair; Chairman Ackermann to depart; CEO Azamian expected to become Chairman.","Expected $30M milestones from LianBio out-license: $10M Dec 2022, $5M Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":15816000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340470,"accession_number":"0001819790-22-000033","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2022-10-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tarsus expands board to nine, appoints Scott Morrison, plans Chairperson transition","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Morrison appointed to Board as Class III director effective Oct 6, 2022, and as Audit Committee Chair.","Board expanded from eight to nine directors; new Commercial Committee formed with Morrison, Yarno, Yeu-Lin, Crane (Chair).","Michael Ackermann expected to transition off Board by end of 2022; Bobak Azamian to become Chairperson, Wendy Yarno Lead Independent Director.","Morrison receives initial equity grant: option for 14,000 shares plus 4,000 RSUs.","Morrison is independent under Nasdaq standards and qualifies as audit committee financial expert."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357751,"accession_number":"0001819790-22-000029","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q2 net loss $5.7M; TP-03 NDA submission for Demodex blepharitis on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.7M vs net income of $6.3M in Q2 2021; revenue $15.3M from LianBio partnership.","Cash and equivalents $245.4M as of June 30, 2022; runway into at least 2026.","TP-03 met all endpoints in Saturn-2 Phase 3; NDA submission expected in H2 2022.","Initiated Ersa Phase 2a trial of TP-03 for Meibomian Gland Disease.","Expecting Phase 1b data for TP-05 Lyme disease prevention in H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":15816000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376347,"accession_number":"0001193125-22-178792","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tarsus shareholders elect 4 Class II directors, ratify E&Y as auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Votes for nominees: Ackermann 10.09M, Azamian 10.22M, Crane 11.04M, Yeu-Lin 10.91M; ~4.27M broker non-votes each.","Ratification of Ernst & Young as auditor approved with 15.32M votes for, 1,027 against, 37 abstain.","Four incumbent directors continue: Link, Chaudhuri, Goldberg, Yarno."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376346,"accession_number":"0001819790-22-000016","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tarsus Q1 net loss $20.2M; TP-03 hits all endpoints in Saturn-2 Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $20.2M vs net income $10.4M YoY; license revenue $0.5M vs $33.4M.","TP-03 met primary and all secondary endpoints in Saturn-2 Phase 3 for Demodex blepharitis; NDA submission H2 2022.","Cash $175.3M at March 31; completed $71M net equity raise in May; cash runway into at least 2026.","TP-05 Phase 1b Callisto data expected H2 2022; TP-04 Phase 2 for rosacea planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":539000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376345,"accession_number":"0001193125-22-139069","cik":1819790,"company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Tarsus prices upsized $75.6M public offering of 5.6M shares at $13.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 5,600,000 shares of common stock at $13.50 per share for gross proceeds of $75.6M.","Underwriters granted 30-day option to purchase up to 840,000 additional shares.","Net proceeds expected to be ~$70.6M after underwriting discounts and expenses.","Offering led by BofA Securities, Jefferies, Barclays, and Raymond James as joint book-runners.","Closing expected on May 5, 2022, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2567885118.585415,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-04T23:59:59+00:00|376345"}